Submitted:
06 June 2025
Posted:
09 June 2025
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Results and Discussion
2.1. FT-IR Analysis of Melissa Oil

2.3. Preparation and Optimization of MelissaNanoemulsions
| Formulations | X1 (Coded Level) | X2 (Coded Level) | Tween 80 (%) X1 | Homogenization time (min) X2 | Particle Size (nm) | Zetapotential |
| 1 | 0 | 0 | 4 | 20 | 147.7 | -25 |
| 2 | 0 | 0 | 4 | 20 | 129.5 | -24.9 |
| 3 | − | − | 2 | 10 | 201.1 | -12.8 |
| 4 | 0 | 0 | 4 | 20 | 132.9 | -25.4 |
| 5 | 0 | A | 4 | 34.1421 | 110.98 | -25 |
| 6 | 0 | 0 | 4 | 20 | 140.8 | -24.1 |
| 7 | + | + | 6 | 30 | 119.1 | -28.7 |
| 8 | − | + | 2 | 30 | 150.6 | -21.8 |
| 9 | a | 0 | 1.17157 | 20 | 160.28 | -15.9 |
| 10 | + | − | 6 | 10 | 181.34 | -22.8 |
| 11 | 0 | 0 | 4 | 20 | 139.67 | -23.7 |
| 12 | A | 0 | 6.82843 | 20 | 132.89 | -25.1 |
| 13 | 0 | a | 4 | 5.85786 | 173.52 | -15.8 |
2.3. Characterization Study of Melissa-Loaded Nanoemulsions (M-NE)
2.4. Physicochemical Characteristics and Morphological Analysis
2.5. Entrapment Efficiency of Melissa Nanoemulsion
2.6. Design and Evaluation of a Melissa Nanoemulgel (M-NG)
2.7. In Vitro Evaluation of Drug Release and Diffusion Profiles

2.8. Assessment of Antibacterial Efficacy
2.9. Examination of Dermal Effects in the Acute Irritation Study
| Time Point | Melissa Nanoemulgel1 | Positive Control (Formalin)1 | Negative Control (Blank Gel)1 | p-value2 |
| 1 hour | 0.5 ± 0.5 | 2.5 ± 0.5 | 0.0 ± 0.0 | 0.0274 |
| 24 hours | 0.0 ± 0.0 | 2.0 ± 0.5 | 0.0 ± 0.0 | 0.0196 |
| 48 hours | 0.0 ± 0.0 | 1.5 ± 0.5 | 0.0 ± 0.0 | 0.0221 |
| 72 hours | 0.0 ± 0.0 | 1.0 ± 0.0 | 0.0 ± 0.0 | 0.0303 |
2.10. In-Vivo Assessment of Anti-Inflammatory Activity
| Time (min) | Negative Control Group (mL)1 | Positive Control Group (mL)1 | Treatment Group (mL)1 | Inhibition of Edema (%) | Group Comparisons | Mean Difference (mL) | p-value4 |
| 0 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | - | - | - | - |
| 30 | 0.42 ± 0.007 | 0.32 ± 0.005 | 0.25 ± 0.006 | 23.82 / 40.5 3 |
Negative Control vs. Standard | -0.17 | 0.029 |
| 60 | 0.41 ± 0.006 | 0.28 ± 0.005 | 0.17 ± 0.004 | 33.2 2 / 60.3 3 |
Negative Control vs. Treatment | -0.24 | 0.008 |
| 120 | 0.39 ± 0.005 | 0.19 ± 0.004 | 0.07 ± 0.003 | 52.6 2 / 81.6 3 |
Standard vs. Treatment | -0.12 | 0.076 |
| 240 | 0.36 ± 0.003 | 0.05 ± 0.001 | 0.01 ± 0.001 | 86.5 2 / 96.9 3 |
- | - | - |
| 360 | 0.33 ± 0.002 | 0.00 ± 0.00 | 0.00 ± 0.00 | 100 2,3 | - | - | - |
3. Conclusion
4. Materials and Methods
4.1. Materials
4.2. Surfactant Screening and FT-IR Analysis of Melissa Oil
4.3. Development and Optimization of Melissa Nanoemulsion
4.4. Assessment of Entrapment Efficiency
4.5. Physicochemical Characterization and Stability Assessment
4.6. Preparation of Melissa Oil – Loaded Nanoemulgel
4.7. Analysis of In Vitro Drug Diffusion and Kinetic Modeling
4.8. Assessment of Antibacterial Potential of M-NG Formulation
4.9. Preclinical Evaluation Using Animal Models
4.10. Evaluation of Skin Irritation Following Topical Application
4.11. Investigation of Anti-Inflammatory Efficacy in Animal Models
4.12. Statistical Analysis and Interpretation
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| QbD | Quality by Design |
| NE | Nanoemulsion |
| NEs | Nanoemulsions |
| M-NE | Melissa Nanoemulsion |
| n-EnM | Nanoemulsion in Matrix |
| n-EnM Hydrogel | Nanoemulsion in Hydrogel |
| M-NG | Meliss Nanoemulgel |
| CCD | Central Composite Design |
| ANOVA | Analysis of Variance |
| PDI | Polydispersity Index |
| CI | Confidence Interval |
| EE | Entrapment Efficiency |
| LOD | Limit of Detection |
| LOQ | Limit of Quantification |
| SEM | Scanning Electron Microscopy |
| UV | Ultraviolet |
| O/W | Oil-in-Water |
| MHB | Mueller-Hinton Broth |
| MIC | Minimum Inhibitory Concentration |
| CLSI | Clinical and Laboratory Standards Institute |
| CFU | Colony-Forming Unit |
| IAEC | Institutional Animal Ethics Committee |
References
- Rinnerthaler, M.; Bischof, J.; Streubel, M. K.; Trost, A.; Richter, K. Oxidative stress in aging human skin. Biomolecules 2015, 5, 545–589. [Google Scholar] [CrossRef] [PubMed]
- D'Orazio, J.; Jarrett, S.; Amaro-Ortiz, A.; Scott, T. UV radiation and the skin. International Journal of Molecular Sciences 2013, 14, 12222–12248. [Google Scholar] [CrossRef] [PubMed]
- Taherkhani, M.; Goudarzi, M.; Bakhshi, A. Antibacterial activity of Melissa officinalis essential oil against clinical isolates of methicillin-resistant Staphylococcus aureus. Iranian Journal of Microbiology 2013, 5, 263–267. [Google Scholar]
- Shakeel, F.; Baboota, S.; Ahuja, A.; Ali, J.; Shafiq, S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. Journal of Nanobiotechnology 2008, 6, 8. [Google Scholar] [CrossRef]
- Kotta, S.; Khan, A. W.; Pramod, K.; Ansari, S. H.; Sharma, R. K.; Ali, J. Exploring scientifically validated herbal nanoformulations for topical delivery: A review. Current Nanoscience 2016, 12, 174–190. [Google Scholar] [CrossRef]
- Bhoyar, N.; Thube, R.; Saudagar, R. Formulation and optimization of nanoemulsion-based gel containing eugenol using response surface methodology. Journal of Drug Delivery and Therapeutics 2021, 11, 183–189. [Google Scholar] [CrossRef]
- Shakeel, F.; Haq, N.; Alanazi, F. K.; Alsarra, I. A.; Raish, M.; Ansari, M. J.; et al. Development of optimized clove oil nanoemulsion using Box–Behnken design: Characterization and evaluation for wound healing activity. Journal of Drug Delivery Science and Technology 2020, 55, 101452. [Google Scholar] [CrossRef]
- Mimica-Dukić; N; Božin, B; Soković; M; Mihajlović; B; Matavulj, M. Antimicrobial and antioxidant activities of Melissa officinalis L. (Lamiaceae) essential oil. Journal of Agricultural and Food Chemistry 2004, 52, 2485–2489. [CrossRef]
- Ali, B.; Al-Wabel, N. A.; Shams, S.; Ahamad, A.; Khan, S. A.; Anwar, F. Essential oils used in aromatherapy: A systemic review. Asian Pacific Journal of Tropical Biomedicine 2015, 5, 601–611. [Google Scholar] [CrossRef]
- Ribeiro, L. N.; Franz-Montan, M.; Breitkreitz, M. C.; de Paula, E.; Groppo, F. C.; Duarte, J. L.; et al. Nanostructured lipid carriers versus nanoemulsions: Effects on lidocaine topical delivery. Journal of Nanoparticle Research 2012, 14, 1–10. [Google Scholar]
- Bouchemal, K.; Briançon, S.; Perrier, E.; Fessi, H. Nano-emulsion formulation using spontaneous emulsification: Solvent, oil and surfactant optimization. International Journal of Pharmaceutics 2004, 280, 241–251. [Google Scholar] [CrossRef] [PubMed]
- Mishra, N.; Tiwari, S.; Verma, A.; Tiwari, G. UV spectrophotometric method development and validation of essential oil of Eucalyptus globulus. Journal of Pharmaceutical Sciences and Bioscientific Research 2013, 3, 28–32. [Google Scholar]
- Danaei, M.; Dehghankhold, M.; Ataei, S.; Hasanzadeh Davarani, F.; Javanmard, R.; Dokhani, A.; et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018, 10, 57. [Google Scholar] [CrossRef] [PubMed]
- Shakeel, F.; Haq, N.; Alanazi, F. K.; Alsarra, I. A.; Ramadan, W.; Faiyazuddin, M. Formulation and optimization of nanoemulsions for topical delivery of hydrophobic drugs: Evaluation of physical stability and particle size. Pharmaceutical Development and Technology 2015, 20, 188–196. [Google Scholar]
- Gadkari, P. N.; Patil, P. B.; Saudagar, R. B. Formulation, development and evaluation of topical nanoemulgel of tolnaftate. Journal of Drug Delivery and Therapeutics 2019, 9, 208–213. [Google Scholar] [CrossRef]
- Choudhury, H.; Gorain, B.; Pandey, M.; Chatterjee, L. A.; Sengupta, P.; Das, A.; et al. Recent update on nanoemulgel as topical drug delivery system. Journal of Pharmaceutical Sciences 2017, 106, 1736–1751. [Google Scholar] [CrossRef]
- Bashir, M.; Ahmad, J.; Asif, M.; Khan, S. U.; Irfan, M.; Ibrahim, A. Y. Nanoemulgel: An innovative carrier for diflunisal topical delivery with profound anti-inflammatory effect: In vitro and in vivo evaluation. International Journal of Nanomedicine 2021, 16, 1457–1472. [Google Scholar] [CrossRef]
- Oktay, A. N.; Karakucuk, A.; Ilbasmis Tamer, S.; Celebi, N. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation. European Journal of Pharmaceutical Sciences 2018, 122, 254–263. [Google Scholar] [CrossRef]
- Mahmoud, R. A.; Hussein, A. K.; Nasef, G. A.; Mansour, H. F. Oxiconazole nitrate solid lipid nanoparticles: Formulation, in vitro characterization and clinical assessment of an analogous loaded carbopol gel. Drug Development and Industrial Pharmacy 2020, 46, 706–716. [Google Scholar] [CrossRef]
- Clinical and Laboratory Standards Institute (CLSI). (2022). Performance standards for antimicrobial susceptibility testing (32nd ed., CLSI supplement M100). Wayne, PA: CLSI.
- Wiegand, I.; Hilpert, K.; Hancock, R.E.W. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nature Protocols 2008, 3, 163–175. [Google Scholar] [CrossRef]
- Shadab, M. D.; Nabil, A. A.; Aldawsari, H. M.; Kotta, S.; Ahmad, J.; Akhter, S. Improved analgesic and anti-inflammatory effect of diclofenac sodium by topical nanoemulgel: Formulation development, in vitro and in vivo studies. Journal of Chemistry 2020, 2020, 1–10. [Google Scholar] [CrossRef]
- El-Leithy, E. S.; Makky, A. M.; Khattab, A. M.; Hussein, D. G. Nanoemulsion gel of nutraceutical co-enzyme Q10 as an alternative to conventional topical delivery system to enhance skin permeability and anti-wrinkle efficiency. International Journal of Pharmacy and Pharmaceutical Sciences 2017, 9, 207–217. [Google Scholar] [CrossRef]
- Burki, I. K.; Khan, M. K.; Khan, B. A.; Uzair, B.; Braga, V. A.; Jamil, Q. A. Formulation development, characterization, and evaluation of a novel dexibuprofen-capsaicin skin emulgel with improved in vivo anti-inflammatory and analgesic effects. AAPS PharmSciTech 2020, 21, 1–4. [Google Scholar] [CrossRef]
- Souto, E. B.; Müller, R. H. Transdermal delivery of ketoprofen using lecithin organogels: Mechanistic studies. AAPS PharmSciTech 2005, 6, E237–E245. [Google Scholar] [CrossRef]




| Observed Wavenumber (cm⁻¹) | Assigned Functional Group | Typical wavenumber Range (cm⁻¹) | Presumed Compound Class |
| 3821.54, 3740.35 | O–H stretch | 3200–3700 | Alcohols, Phenols |
| 3498.79 | H-bonded O–H stretch | 3200–3600 | Phenolics, Hydroxyl groups |
| 2921.97, 2863.12, 2734.83 | C–H stretch | 2800–3000 | Alkanes (saturated hydrocarbons) |
| 1730.00, 1672.26 | C=O stretch | 1650–1750 | Esters, Ketones |
| 1510.91, 1445.89, 1378.71 | C=C stretch, CH bend | 1350–1600 | Aromatics, Alkanes, Alkenes |
| 1237.02, 1180.75, 1113.96, 1025.96 | C–O stretch | 1000–1300 | Alcohols, Ethers |
| 987.69, 925.59 | =C–H bending | 800–1000 | Terpenes, Aromatics |
| 835.55, 750.74, 693.16 | C–H out-of-plane bend | 650–900 | Aromatic or cyclic compounds |
| 593.15, 533.13, 459.41 | Fingerprint region | <600 | Specific spectral features |
| Factor | df | Overall Variability | Mean Square | F-Statistic | p-Value | Statistical Significance |
| Model | 5 | 6564.29 | 1312.86 | 12.47 | 0.0021 | Significant |
| Error | 7 | 736.71 | 105.24 | – | – | – |
| Total | 12 | 7301 | – | – | – | – |
| Intercept | – | – | 143.92 | 28.72 | <0.0001 | Highly significant |
| Tween 80 | 1 | – | −23.56 | −4.11 | 0.0047 | Highly significant |
| Homogenization Time | 1 | – | −27.89 | −5.24 | 0.0022 | Highly significant |
| Tween 80 × Homogenization Time | 1 | – | 1.89 | 0.34 | 0.7442 | Not significant |
| Tween 80 × Tween 80 | 1 | – | 9.63 | 2.71 | 0.0481 | Marginally significant |
| Homogenization Time × Time | 1 | – | 5.74 | 1.28 | 0.2417 | Not significant |
| R2 | – | 0.8992 | – | – | – | Indicates strong model fit |
| Adjusted R2 | – | 0.8465 | – | – | – | Adjusted for predictors |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).